JP2014508784A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2014508784A5 JP2014508784A5 JP2014500216A JP2014500216A JP2014508784A5 JP 2014508784 A5 JP2014508784 A5 JP 2014508784A5 JP 2014500216 A JP2014500216 A JP 2014500216A JP 2014500216 A JP2014500216 A JP 2014500216A JP 2014508784 A5 JP2014508784 A5 JP 2014508784A5
- Authority
- JP
- Japan
- Prior art keywords
- treatment
- radiolabeled compound
- cancer
- radioactive imaging
- breast cancer
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 206010006187 Breast cancer Diseases 0.000 claims 1
- 208000026310 Breast neoplasm Diseases 0.000 claims 1
- 206010060862 Prostate cancer Diseases 0.000 claims 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims 1
- 150000001875 compounds Chemical class 0.000 claims 1
- 238000003384 imaging method Methods 0.000 claims 1
- 230000002285 radioactive effect Effects 0.000 claims 1
Claims (1)
- 放射性イメージングまたは乳癌または前立腺癌の治療のための、請求項４５に記載の放
射標識化合物。
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161467764P | 2011-03-25 | 2011-03-25 | |
| US61/467,764 | 2011-03-25 | ||
| PCT/CA2012/000316 WO2012129673A1 (en) | 2011-03-25 | 2012-03-26 | INHIBITORS OF 17ß-HSD1, 17ß-HSD3 AND 17ß-HSD10 |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017253315A Division JP6727184B2 (ja) | 2011-03-25 | 2017-12-28 | １７β−ＨＳＤ１、１７β−ＨＳＤ３、および１７β−ＨＳＤ１０の阻害剤 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2014508784A JP2014508784A (ja) | 2014-04-10 |
| JP2014508784A5 true JP2014508784A5 (ja) | 2016-10-27 |
Family
ID=46929260
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014500216A Withdrawn JP2014508784A (ja) | 2011-03-25 | 2012-03-26 | １７β−ＨＳＤ１、１７β−ＨＳＤ３、および１７β−ＨＳＤ１０の阻害剤 |
| JP2017253315A Active JP6727184B2 (ja) | 2011-03-25 | 2017-12-28 | １７β−ＨＳＤ１、１７β−ＨＳＤ３、および１７β−ＨＳＤ１０の阻害剤 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017253315A Active JP6727184B2 (ja) | 2011-03-25 | 2017-12-28 | １７β−ＨＳＤ１、１７β−ＨＳＤ３、および１７β−ＨＳＤ１０の阻害剤 |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US11072632B2 (ja) |
| EP (1) | EP2688901B1 (ja) |
| JP (2) | JP2014508784A (ja) |
| AU (1) | AU2012234682A1 (ja) |
| CA (1) | CA2830984C (ja) |
| WO (1) | WO2012129673A1 (ja) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9850272B2 (en) | 2013-06-25 | 2017-12-26 | Forendo Pharma Ltd. | Therapeutically active estratrienthiazole derivatives as inhibitors of 17.beta-hydroxy-steroid dehydrogenase, type 1 |
| US10377791B2 (en) | 2013-06-25 | 2019-08-13 | Forendo Pharma Ltd. | Therapeutically active estratrienthiazole derivatives as inhibitors of 17 B-hydroxysteroid dehydrogenase, type 1 |
| WO2015169971A1 (en) * | 2014-05-09 | 2015-11-12 | Tangent Reprofiling Limited | Modulators of androgen synthesis |
| JP6407415B2 (ja) * | 2014-09-11 | 2018-10-17 | バイエル・ファルマ・アクティエンゲゼルシャフト | ３−窒素または硫黄置換エストラ−１，３，５（１０），１６−テトラエンａｋｒ１ｃ３阻害剤 |
| CZ307437B6 (cs) | 2016-06-07 | 2018-08-22 | Ăšstav organickĂ© chemie a biochemie AV ÄŚR, v.v.i. | 15β-substituované deriváty estronu jako selektivní inhibitory 17β-hydroxysteoiddehydrogenáz |
| UA126342C2 (uk) | 2017-06-08 | 2022-09-21 | Форендо Фарма Лтд | 15-бета-[3-пропанамідо]-заміщені естра-1,3,5(10)-трієн-17-он-сполуки і їх 17-оксими для використання в інгібуванні 17-бета-гідроксистероїддегідрогеназ |
| WO2024020520A2 (en) * | 2022-07-20 | 2024-01-25 | Board Of Regents, The University Of Texas System | Enzyme compositions, steroid derivatives, enzyme inhibitors, and methods of making same for pharmaceutical applications |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5232917A (en) * | 1987-08-25 | 1993-08-03 | University Of Southern California | Methods, compositions, and compounds for allosteric modulation of the GABA receptor by members of the androstane and pregnane series |
| EP0559240B1 (en) * | 1987-09-24 | 2001-12-05 | Jencap Research Limited | Contraceptive packages containing oestrogen and progestin |
| TW385308B (en) * | 1994-03-04 | 2000-03-21 | Merck & Co Inc | Prodrugs of morpholine tachykinin receptor antagonists |
| US5952319A (en) * | 1997-11-26 | 1999-09-14 | Research Triangle Institute | Androgenic steroid compounds and a method of making and using the same |
| US6933312B2 (en) * | 2002-10-07 | 2005-08-23 | Agouron Pharmaceuticals, Inc. | Pyrazole derivatives |
| TWI331154B (en) | 2003-11-12 | 2010-10-01 | Solvay Pharm Gmbh | Novel 17-hydroxysteroid dehydrogenase type i inhibitors |
| CN102796160A (zh) | 2005-05-26 | 2012-11-28 | 索尔瓦药物有限公司 | 17β-HSD1和STS抑制剂 |
| US10174070B2 (en) * | 2005-09-30 | 2019-01-08 | Endece Llc | 6-substituted estradiol derivatives and methods of use |
| AU2007299010B2 (en) * | 2006-09-19 | 2013-01-31 | Solvay Pharmaceuticals Gmbh | Estratriene derivatives and their uses as 17beta-hydroxysteroid dehydrogenase inhibitors |
| RU2453554C2 (ru) | 2006-11-30 | 2012-06-20 | Зольвай Фармасьютиклз Гмбх | Замещенные производные эстратриена как ингибиторы 17бета hsd |
| US20080171728A1 (en) | 2007-01-12 | 2008-07-17 | Quatrx Pharmaceuticals Co. | Efficient Process for Preparing Steroids and Vitamin D Derivatives With the Unnatural Configuration at C20 (20 Alpha-Methyl) from Pregnenolone |
| EP2014672A1 (en) * | 2007-07-12 | 2009-01-14 | Bayer Schering Pharma Aktiengesellschaft | 8-beta-substituted estratrienes as selectively active estrogens |
-
2012
- 2012-03-26 EP EP12765822.7A patent/EP2688901B1/en active Active
- 2012-03-26 US US14/007,577 patent/US11072632B2/en active Active
- 2012-03-26 JP JP2014500216A patent/JP2014508784A/ja not_active Withdrawn
- 2012-03-26 CA CA2830984A patent/CA2830984C/en active Active
- 2012-03-26 WO PCT/CA2012/000316 patent/WO2012129673A1/en active Application Filing
- 2012-03-26 AU AU2012234682A patent/AU2012234682A1/en not_active Abandoned
-
2017
- 2017-12-28 JP JP2017253315A patent/JP6727184B2/ja active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ZA201907607B (en) | Labeled inhibitors of prostate specific membrane antigen (psma), their use as imaging agents and pharmaceutical agents for the treatment of prostate cancer | |
| JP2014508784A5 (ja) | ||
| EA201400178A1 (ru) | Лечение рака молочной железы | |
| EP2825669A4 (en) | METHOD AND COMPOSITIONS FOR DIAGNOSIS, FORECASTING AND TREATING ACUTE MYELOIC LEUKEMIA | |
| PT4095130T (pt) | Inibidores marcados do antígeno de membrana específico da próstata (psma), seu uso como agentes de imagem e agentes farmacêuticos para o tratamento do cancro da próstata | |
| PT3089749T (pt) | Preparações combinadas para o tratamento de cancro | |
| HK1219737A1 (zh) | 用於治療癌症的新化合物 | |
| PL3011321T3 (pl) | Obrazowanie rentgenowskie z kodowaną przesłoną | |
| PL3053578T3 (pl) | Skojarzona terapia przeciwnowotworowa z zastosowaniem związku azabicyklicznego | |
| DK2802351T3 (da) | Midler til behandling af triple-negativ brystkræft | |
| IL237976A0 (en) | A derivative of 7-azaindole-2,7-naphthyridine for the treatment of tumors | |
| SG11201506407VA (en) | Kit for tumor imaging | |
| IL245551A0 (en) | Anti-matriptase antibodies for cancer treatment | |
| EP2983693A4 (en) | SEPT4 / ARTS AS A TUMOR SUPPRESSOR IN THE DIAGNOSIS, PROGNOSIS AND TREATMENT OF HEPATIC DISORDERS | |
| LT2984108T (lt) | Anti-s100a7 antikūnai, skirti vėžio gydymui ir diagnozei | |
| IL245477B (en) | Diagnosis of lung cancer | |
| SG11201911602RA (en) | 18f-labelled compound for prostate cancer diagnosis, and use thereof | |
| PL3016948T3 (pl) | 2-acyloaminotiazole do leczenia nowotworów | |
| AP2015008905A0 (en) | Novel compounds for the treatment of cancer | |
| JP2012092693A5 (ja) |